Skip to main content
SpringerLink
Log in

Patients with lung cancer who continue using Avastin [bevacizumab] beyond the median treatment duration will receive the drug free of charge,

  • News item
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Bruce M.Avastin for lung cancer will be free to patients who beat the average. FDC Reports - Pink Sheet - Prescription Pharmaceuticals and Biotechnology 68: 6, No. 42, 16 Oct 2006

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Patients with lung cancer who continue using Avastin [bevacizumab] beyond the median treatment duration will receive the drug free of charge,. Pharmacoecon. Outcomes News 517, 11 (2006). https://doi.org/10.2165/00151234-200605170-00031

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200605170-00031

Keywords

Search

Navigation